In summary, during the last ten years the most remarkable advantage has become accomplished in HER2/neu-overexpressing MBC. Introduction of bevacizumab as a VEGF-directed specific remedy continues to be an issue on discussion. Some of the novel therapeutics into the breast cancer armamentarium r